Photo by Nhia Moua on Unsplash

Columbia University Medical Center demonstrates regeneration of severely damaged donor lungs, potentially increasing supply of donor lungs

About 80 percent of the already limited supply of donor lungs are too damaged to be considered for transplantation, according to senior author Matthew Bacchetta, MD, MBA, MA, associate professor of Thoracic and Cardiac Surgery at Vanderbilt University Medical Center. A new technique to rehabilitate lungs that are too damaged to be considered for transplant could benefit an increasing population of patients with end-stage lung disease. Bacchetta and colleagues from Columbia...

Audentes Therapeutics Presents Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy

At the 22nd Annual Meeting of the American Society of Gene and Cell Therapy, promising results for the AT132 genetic therapy for X-linked Myotubular Myopathy ( XLMTM ) were presented. XLMTM is a rare neuromusclular condition that is caused by mutations in the MTM1 gene. This results in extreme muscle weakness, and a majority of patients require a ventilator to continue breathing, as well as a gastrostomy tube for nutritional support. The average lifespan...

CRISPR used to treat deadly lung disease before birth in animal trial

Using CRISPR gene editing technology, a team from Children's Hospital of Philadelphia and Penn Medicine have managed to edit a harmful mutation that causes death within hours after birth, in an early proof of concept study with mice. The gene in question is responsible for creating a surfactant in the lungs, which is part of a protective film that shields the lungs' alveoli from being collapsed due to the fluid mechanics of water particles,...